Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Abbisko Therapeutics Co., Ltd. violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects Abbisko Therapeutics Co., Ltd.: Form 483 with 1 Citations (March 20, 2026)

Key facts

Firm	Abbisko Therapeutics Co., Ltd.
FEI / inspection ID	3020982471
Inspection end date	March 20, 2026
Citation count	1

In short: FDA inspected Abbisko Therapeutics Co., Ltd. in China and issued a Form 483 listing 1 inspectional observation following an inspection that concluded 2026-03-20. FDA's inspection record does not classify Abbisko Therapeutics Co., Ltd.'s facility type further. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record. A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — -- 1 of 2 -- The observations of objectionable conditions and practices listed on the f

-- 1 of 2 -- The observations of objectionable conditions and practices listed on the f ront of this f orm are reported: 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or 2. To assist f irms inspected in complying with the Acts and regulations enf orced by the Food and Drug Administration. Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides: "Upon completion of any such inspection of a f actory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the of f icer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting f orth any conditions or practices observed by him which, in his judgment, indicate that any f ood, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any f ilthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with f ilth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary." -- 2 of 2 -- A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Abbisko Therapeutics Co., Ltd.’s FDA history

Argus HQ has recorded 1 total FDA action tied to Abbisko Therapeutics Co., Ltd.: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Abbisko Therapeutics Co., Ltd. violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Abbisko Therapeutics Co., Ltd.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Inspects Abbisko Therapeutics Co., Ltd.: Form 483 with 1 Citations (March 20, 2026). Digital Empire Holdings LLC. Retrieved from https://argushq.ai/483/abbisko-therapeutics-3020982471-2026-03-20

MLA

"FDA Inspects Abbisko Therapeutics Co., Ltd.: Form 483 with 1 Citations (March 20, 2026)." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/483/abbisko-therapeutics-3020982471-2026-03-20.

Chicago

Argus HQ Research. "FDA Inspects Abbisko Therapeutics Co., Ltd.: Form 483 with 1 Citations (March 20, 2026)." Digital Empire Holdings LLC. Accessed August 17, 2026. https://argushq.ai/483/abbisko-therapeutics-3020982471-2026-03-20.

BibTeX

@misc{argushq_argushq_ai_483_abbisko_therapeutics_3020982471_2026_03_20_2026,
  title = {FDA Inspects Abbisko Therapeutics Co., Ltd.: Form 483 with 1 Citations (March 20, 2026)},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/483/abbisko-therapeutics-3020982471-2026-03-20},
  note = {Accessed: August 17, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗